BofA lowered the firm’s price target on Janux Therapeutics (JANX) to $49 from $58 and keeps a Buy rating on the shares after the company announced updated interim data for JANX007 from the Phase 1 clinical program in patients with mCRPC. The firm still thinks ‘007 is “a viable drug with a reasonable safety profile and the potential to show a benefit in OS over Pluvicto,” says the analyst, who views the 43% move lower in shares as “overdone” despite calling the latest Phase 1 update “admittedly mixed.” The firm lowers its price target as it pushes back expectations for a JANX007 launch to 2028 and reduces its peak market share estimate to 15% from 20%.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Buy Rating Reaffirmed for JANX007 Amid Promising Survival Metrics and Competitive Positioning
- Buy Rating Affirmed for JANX007 Amid Promising Phase 1 Data and Market Dislocation
- Janux Therapeutics price target lowered to $45 from $70 at H.C. Wainwright
- Optimistic Long-term Potential for Janux Therapeutics Despite Current Challenges
- Janux Therapeutics price target lowered to $32 from $80 at Clear Street